Healthcare


 Pacific Smiles Sees Strong Start to FY2025 with 10.9% Increase in Patient Fees

Pacific Smiles Sees Strong Start to FY2025 with 10.9% Increase in Patient Fees

August 28, 2024 10:05 AM AEST| By Team Kalkine Media

Pacific Smiles Group (ASX: PSQ) has reported a promising start to the 2024-25 financial year, with patient fees rising by 10.9% to $50.8 million in the first two months. This positive momentum reflects the company’s efforts to enhance the utilization...

 Nanosonics (ASX:NAN) Shares Surge 11.85% on FY24 Results

Nanosonics (ASX:NAN) Shares Surge 11.85% on FY24 Results

August 27, 2024 05:17 PM AEST| By Team Kalkine Media

Nanosonics Ltd (ASX:NAN) saw a significant boost in its share price on Tuesday, rising 11.85% to AU$3.02 following the release of its full-year FY24 results. The stock, which opened at AU$2.86, climbed to an intraday high of AU$3.08 as investors reac...

 Actinogen Medical's (ASX:ACW) sharer price jumps 463% in 5 years, drops 47% in a month

Actinogen Medical's (ASX:ACW) sharer price jumps 463% in 5 years, drops 47% in a month

August 27, 2024 05:01 PM AEST| By Team Kalkine Media

Actinogen Medical Limited (ASX:ACW) has seen a sharp 47% decline in its share price over the past month, leaving shareholders concerned about the short-term outlook. However, when viewed over a more extended period, the company’s performance remains...

 Tryptamine Therapeutics (ASX:TTM) Completes First-Ever IV Psilocin Injections to Set Safety Baseline

Tryptamine Therapeutics (ASX:TTM) Completes First-Ever IV Psilocin Injections to Set Safety Baseline

August 26, 2024 12:17 PM AEST| By Team Kalkine Media

Headlines:,Completion of Initial Study:,Tryptamine Therapeutics (ASX:TYP) has finalized its first intravenous (IV) psilocin injection study with 11 patients, focusing on establishing baseline safety data.,Safety and Dosage Focus:,The study, involving...

 Actinogen's Xanamem Shows Notable Advances with Four-Week 10mg Daily Regimen

Actinogen's Xanamem Shows Notable Advances with Four-Week 10mg Daily Regimen

August 26, 2024 11:27 AM AEST| By Team Kalkine Media

Headlines,Promising Results for Xanamem:,Actinogen’s novel antidepressant, Xanamem, has shown significant efficacy in treating major depression with a daily 10mg dose, leading to a 30% increase in the company's share price.,Unique Mechanism of Action...

 Fisher & Paykel (ASX: FPH) Updates Profit Forecast for FY25

Fisher & Paykel (ASX: FPH) Updates Profit Forecast for FY25

August 23, 2024 10:34 AM AEST| By Team Kalkine Media

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) has revised its profit forecast for the fiscal year 2025, anticipating a net profit after tax (NPAT) of between $320 million and $370 million. This forecast represents an increase from the previou...

 Clarity Pharmaceuticals and Next Science: Key Updates in the Biotech Sector

Clarity Pharmaceuticals and Next Science: Key Updates in the Biotech Sector

August 22, 2024 06:25 PM AEST| By Team Kalkine Media

Clarity Pharmaceuticals,(ASX: CU6),has received a significant boost with the FDA granting 'Fast Track' designation to its new imaging agent, 64Cu-SAR-bisPSMA, designed for detecting prostate cancer. This designation is set to accelerate the developme...

 US FDA Grants Fast Track Status to Clarity Pharma’s (ASX:CU6) Innovative Prostate Cancer PET Imaging Compound

US FDA Grants Fast Track Status to Clarity Pharma’s (ASX:CU6) Innovative Prostate Cancer PET Imaging Compound

August 22, 2024 11:57 AM AEST| By Team Kalkine Media

Highlights:,FDA Fast Track Status,:,Clarity Pharmaceuticals has received fast track status from the US FDA for its prostate cancer imaging compound, 64Cu-SAR-bisPSMA, which is designed for PET scans.,Accelerated Approval,:,The,fast track,designation...

 Osteopore (ASX:OSX) Completes 3D-Printed Bone Implant Study Funded by Chilean Government

Osteopore (ASX:OSX) Completes 3D-Printed Bone Implant Study Funded by Chilean Government

August 22, 2024 10:30 AM AEST| By Team Kalkine Media

Osteopore Limited (ASX:OSX),has successfully concluded a research program funded by the Chilean government, focused on developing a 3D-printed bone implant designed to enhance regenerative healing. This research marks a significant milestone for the...

 Healius Ltd (ASX:HLS) Shares Surge 9% After Full-Year Results Amidst ASX 200 Decline

Healius Ltd (ASX:HLS) Shares Surge 9% After Full-Year Results Amidst ASX 200 Decline

August 21, 2024 02:57 PM AEST| By Team Kalkine Media

Healius Ltd (ASX:HLS), a prominent player in the pathology and imaging sector, is enjoying a notable boost in its share price today. While the S&P/ASX 200 Index (ASX: XJO) has dipped by 0.5%, Healius shares have surged by 8.8%, climbing to AU$1.60 fr...

 EBOS Group (ASX:EBO)Sees Bright Future Despite Recent Setbacks

EBOS Group (ASX:EBO)Sees Bright Future Despite Recent Setbacks

August 21, 2024 11:48 AM AEST| By Team Kalkine Media

EBO.AX: EBOS Group (ASX:EBO), the New Zealand-based healthcare and pet products company, is moving forward with renewed confidence after a successful year. Despite a failed attempt to acquire Greencross in late 2023, EBOS has reported record sales an...

 Healius Suspends Dividend Amid Increased Losses

Healius Suspends Dividend Amid Increased Losses

August 21, 2024 11:02 AM AEST| By Team Kalkine Media

Healius Ltd, a prominent,ASX healthcare stock,in the Australian pathology sector, has recently released its financial results for the fiscal year 2024 (FY24), revealing a challenging year marked by deepened losses. Despite a modest increase in revenu...

 INOVIQ (ASX:IIQ) Announces Blood Test for Parkinson’s Disease, Building on Alzheimer’s Success

INOVIQ (ASX:IIQ) Announces Blood Test for Parkinson’s Disease, Building on Alzheimer’s Success

August 20, 2024 11:27 AM AEST| By Team Kalkine Media

INOVIQ (ASX:IIQ) saw its shares rise by 6% on Tuesday following the company’s announcement of a breakthrough in blood testing for Parkinson’s Disease (PD). This new development comes on the heels of a similar success with Alzheimer’s Disease (AD) rep...

 ASX Health Stocks: LTR Pharma’s ED Therapy Advances Under TGA Scheme

ASX Health Stocks: LTR Pharma’s ED Therapy Advances Under TGA Scheme

August 16, 2024 05:26 PM AEST| By Team Kalkine Media

LTR Pharma Ltd (ASX:LTP) has reached a significant milestone in the launch of its nasal spray treatment for erectile dysfunction (ED), with the first select group of patients receiving Spontan under the Therapeutic Goods Administration (TGA) Authoris...

 Cochlear Ltd (ASX: COH) Faces Share Price Drop Despite Positive Results

Cochlear Ltd (ASX: COH) Faces Share Price Drop Despite Positive Results

August 16, 2024 01:47 PM AEST| By Team Kalkine Media

Cochlear Ltd, a prominent player in the hearing implant sector, saw its share price fall by 7% following the release of its financial results for the fiscal year 2024 (FY24). Despite reporting robust financial and operational performance for the year...

 Wellnex (ASX:WNX) Announces First Special Access Scheme Prescriptions for New Wellness Life Brand

Wellnex (ASX:WNX) Announces First Special Access Scheme Prescriptions for New Wellness Life Brand

August 16, 2024 10:09 AM AEST| By Team Kalkine Media

Wellnex (ASX:WNX) has reached a significant milestone with the launch of its Wellness Life brand, now available through the Therapeutic Goods Administration's (TGA) Special Access Scheme (SAS). This marks the first set of prescriptions for Wellness L...

 Cochlear (ASX:COH) Shares Dive After Disappointing Profit Forecast

Cochlear (ASX:COH) Shares Dive After Disappointing Profit Forecast

August 15, 2024 12:26 PM AEST| By Team Kalkine Media

Shares in Cochlear (ASX:COH) plummeted over 8% on Thursday after the Australian hearing implants maker revealed a profit forecast for the current fiscal year that fell short of market expectations. This unexpected forecast prompted a sharp sell-off,...

 Pro Medicus Ltd (ASX: PME) Share Price Soars After Impressive FY24 Results

Pro Medicus Ltd (ASX: PME) Share Price Soars After Impressive FY24 Results

August 14, 2024 04:59 PM AEST| By Team Kalkine Media

Pro Medicus Ltd,(ASX: PME),is enjoying a notable boost in its share price, which has risen by 8% following the release of its robust FY24 financial results. The company, renowned for its expertise in healthcare informatics, offers a comprehensive sui...

 Immutep (ASX: IMM) Doses First Human Patient with IMP761 – Potential Broad-Spectrum Autoimmune Treatment

Immutep (ASX: IMM) Doses First Human Patient with IMP761 – Potential Broad-Spectrum Autoimmune Treatment

August 14, 2024 10:33 AM AEST| By Team Kalkine Media

Highlights:,First,Human Dosing of IMP761,:,Immutep,(ASX: IMM) has,initiated,its first human trial for IMP761, a new autoimmune treatment based on LAG-3, aiming to modulate malfunctioning T cells associated with autoimmune diseases.,Targeted,Autoimmun...

 Anteris Technologies, LTR Pharma, and CSL Boost ASX with Worthfull Results

Anteris Technologies, LTR Pharma, and CSL Boost ASX with Worthfull Results

August 13, 2024 05:42 PM AEST| By Team Kalkine Media

Anteris Technologies,(ASX: AVR),is set to relocate its headquarters to the United States, transitioning to Anteris Technologies Global Corp. (Holdco). This strategic move involves a re-domiciliation process where Holdco will become the new parent com...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.